FDA approves updated label for Lilly’s Amyvid (florbetapir F 18 injection) to support diagnosis of Alzheimer’s disease in patients
INDIANAPOLIS, JUNE 25, 2025 – Eli Lilly and Company (NYSE: LLY) announced that the U.S. FDA has approved a label update for Amyvid (florbetapir F 18 injection) for intravenous use. Amyvid is used for brain imaging to estimate amyloid plaque density in patients with cognitive impairment being
